Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.

Cancer Med · 2022 · PMC8986145 · PMID 35138046

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

moderately significantno p-value reported

Based on such numbers, the efficacy of salvage use of nivolumab plus ipilimumab can be little (4%) or moderately significant (25%).

also in 2,178 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.